Abstract
Summary The management of high-risk and advanced prostate cancer had a major paradigm shift over the past decade. From the Huggins’ era of sole androgen deprivation therapy (ADT), the management has evolved to novel androgen receptor signaling inhibitors (ARSI), chemotherapy, targeted molecular, immunotherapy, and radiotheranostics. The management of advanced prostate cancer is broadly studied under metastatic hormone or castration-sensitive prostate cancer (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC). The mCSPC has evolved from mere ADT to the use of abiraterone, enzalutamide, and docetaxel-based chemotherapy and the burning conflict of treatment intensification with triplet therapy. Various novel agents, such as poly (ADP-ribose) polymerase inhibitors (PARPIs) and radiotheranostics, are being explored in the management of mCSPC. The management of mCRPC has evolved from mitoxantrone to docetaxel-based therapy, novel ARSI therapy, PARPI, 177 lutetium-prostate-specific membrane antigen-617, or novel-targeted therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
